Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The safety of autologous adipose derived SVF combined with the ACAM2000 (Vaccinia) vaccine in patients with advanced solid tumors

Trial Profile

The safety of autologous adipose derived SVF combined with the ACAM2000 (Vaccinia) vaccine in patients with advanced solid tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2018

At a glance

  • Drugs SI 001 (Primary) ; SI 001 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Calidi Biotherapeutics
  • Most Recent Events

    • 06 Nov 2018 According to a Calidi Biotherapeutics media release, data from this trial ( safety findings and post-treatment observations of oncolytic vaccinia virus combined with adipose stromal vascular fraction (SVF) cells in autologous settings) will be presented at the Society for Immunotherapy of Cancer (SITC) upcoming 33rd Annual Meeting (7-11 Nov 2018, Washington, D.C.).
    • 31 Oct 2018 Results of this trial published online on Calidi Biotherapeutics website.
    • 30 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top